Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,506 JPY | +3.51% | +1.72% | -10.68% |
04-25 | Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024 | |
04-25 | Astellas Pharma Inc. Announces Board and Committee Retirements | CI |
Business Summary
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Number of employees: 14,484
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 1,296,163 | 100.0 % | 1,518,619 | 100.0 % | +17.16% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
43.0
%
| 537,452 | 41.5 % | 652,441 | 43.0 % | +21.40% |
Established Markets
23.6
%
| 315,162 | 24.3 % | 358,407 | 23.6 % | +13.72% |
Japan
17.3
%
| 258,758 | 20.0 % | 262,303 | 17.3 % | +1.37% |
International
9.5
%
| 110,081 | 8.5 % | 144,735 | 9.5 % | +31.48% |
Greater China
5.3
%
| 66,305 | 5.1 % | 80,011 | 5.3 % | +20.67% |
Other
1.4
%
| 8,406 | 0.6 % | 20,722 | 1.4 % | +146.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 31/03/86 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 10-31 |
Kenji Yasukawa
CHM | Chairman | 63 | 31/03/86 |
Compliance Officer | - | 30/09/22 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 65 | 31/08/06 | |
Noriyuki Uematsu
BRD | Director/Board Member | 63 | 31/05/16 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 31/03/83 |
Atsushi Kamide
IRO | Public Communications Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 31/05/21 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 31/05/17 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 31/03/86 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 31/05/19 |
Noriyuki Uematsu
BRD | Director/Board Member | 63 | 31/05/16 |
Eriko Sakurai
BRD | Director/Board Member | 63 | - |
Director/Board Member | 65 | 31/08/06 | |
Haruko Shibumura
BRD | Director/Board Member | 59 | 31/05/19 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 31/03/83 |
Hiroo Sasaki
BRD | Director/Board Member | 68 | 31/05/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,809,663,075 | 1,788,505,828 ( 98.83 %) | 16,561,677 ( 0.9152 %) | 98.83 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
8,333,333 | 8.64% | 26,583,332 $ | |
7,266,342 | 3.89% | 20,854,402 $ | |
FIBROGEN, INC. 5.03% | 4,968,367 | 5.03% | 11,675,662 $ |
ASTELLAS PHARMA INC. 0.04% | 731,000 | 0.04% | 7,938,141 $ |
ONCOLYS BIOPHARMA INC. 3.59% | 727,200 | 3.59% | 3,791,075 $ |
Company contact information
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho Chuo-Ku
103-8411, Tokyo
+81 3 3244 3000
http://www.astellas.comGroup companies
Name | Category and Sector |
---|---|
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The private company is based in Leiden, Netherlands. |
Financial Conglomerates
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.68% | 17.15B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4503 Stock
- Company Astellas Pharma Inc.